DLBCL
Conditions
Interventions
A: Newly diagnosed large B-cell lymphoma:No
B: Patients with relapsed, refractory or newly diagnosed large B-cell lymphoma who are preparing for hematopoietic stem cell transplantation or CAR-T therapy:No
Sponsors
Hematology Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: To be eligible for inclusion in this study, subjects must meet all of the following criteria: 1) Patients fully understand this study, voluntarily participate and sign the informed consent; 2) The age is greater than 18 years old, and the gender is not limited; 3) Newly diagnosed large B-cell lymphoma confirmed by histopathology, or patients with relapsed or refractory large B-cell lymphoma who are ready to receive hematopoietic stem cell transplantation or CAR-T therapy; 4) There must be at least 1 evaluable or measurable lesion that meets Lugano2014 criteria; 5) Able to cooperate with the collection of samples from each node and provide corresponding clinical information.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria are not eligible for this study: 1) Active hepatitis B, hepatitis C infection or human immunodeficiency virus (HIV) infection; 2) Suffering from other lymphoid malignancies at the same time 3) Patients who are judged by the investigator to be unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity;specificity;PPV;NPV; | — |
Countries
China
Contacts
Public ContactQiu Lugui
Hematology Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
Outcome results
None listed